The central question is changing: not simply "did an athlete report symptoms?", but "what can we measure about their exposure and biological response over time?"

For decades, concussion and repetitive head-impact management have relied heavily on what athletes feel, report and display: headaches, dizziness, memory difficulty, altered mood, or changes in balance and behaviour.

Those assessments remain essential, but they are incomplete. Symptoms can be delayed, fluctuate over time, or go unreported. Even people with similar exposure may respond very differently.

A new generation of research is beginning to close that measurement gap. Blood biomarkers, imaging, cognitive assessment, and wearable impact data are increasingly being studied together, laying the foundations for a more objective approach to brain health.

It is too early to claim that a blood test, wearable sensor or single metric can diagnose concussion or predict who will later develop neurological disease. The stronger and more useful message is that biological responses associated with head-impact exposure are becoming measurable.

That distinction matters. Objective measurement does not replace clinical judgement, and it should not be used to create certainty where the science does not yet support it. Instead, it offers another layer of evidence that may help researchers and clinicians understand exposure, recovery, and individual response more clearly.

A 2025 study in Scientific Reports examined nine former professional boxers and compared their results with two groups: people with subjective cognitive decline and people with biomarker-confirmed Alzheimer's disease.

The researchers combined blood-based biomarkers, MRI brain imaging, and neuropsychological testing. The former boxers showed higher plasma concentrations of GFAP, p-tau181, and p-tau217 than the subjective cognitive decline comparison group, alongside lower volumes in several pre-specified brain regions associated with neurodegenerative disease.

The study did not diagnose chronic traumatic encephalopathy, and its small sample means the findings should be interpreted cautiously. However, it did identify biological signals consistent with neuronal damage and neurodegenerative risk, despite no clear group-level difference in neuropsychological test performance compared with the subjective cognitive decline group.

Five boxers also had follow-up measurements approximately seven years later. Within this small subgroup, NfL and p-tau181 increased significantly over time, adding to the case for larger longitudinal studies.

A 2026 JAMA Neurology study led by Marloes I. Hoppen followed 302 adult amateur football players in the Netherlands. Blood samples were collected before and after organised matches, and video analysis was used to quantify the frequency and intensity of heading exposure.

Heading exposure was associated with acute increases in p-tau217 and S100B, with evidence of dose-response relationships: greater exposure was linked with larger biomarker changes.

This does not mean that a single match, or an individual header, causes permanent brain injury. It does show that routine sporting exposure can be accompanied by measurable short-term biological responses, even in real-world play rather than a laboratory setting.

The studies examine different populations, timeframes and research questions, so they should not be presented as a direct causal sequence from football heading to later-life neurodegeneration.

Together, however, they illustrate the direction of travel. Researchers can now measure both acute biological responses following repetitive head impacts and longer-term biological differences in people with substantial lifetime exposure.

The next major step is correlation: combining accelerometry-based exposure data with biomarkers, imaging, symptoms, cognitive testing, and recovery information. No single dataset can explain brain health on its own. Their value increases when they are studied together over time.

The practical opportunity is not a single test that declares an athlete safe or unsafe. It is a more complete monitoring framework that can track exposure, biological response, and recovery over time.

If validated in larger and more diverse studies, this approach could support research into baseline variation, longitudinal athlete monitoring, recovery, cumulative exposure, and the identification of people who may warrant further clinical assessment.

This matters beyond elite competition. The same measurement challenge exists in youth and community sport, military training, emergency services and other settings where repeated head impacts may occur.

HIT's role is to make head-impact exposure visible. The HIT platform records linear acceleration and rotational velocity, helping athletes, teams, and researchers build an objective record of individual events and cumulative exposure over time.

HIT does not diagnose concussion, measure blood biomarkers, or replace medical assessment. Its value is as one part of a wider measurement ecosystem, providing exposure data that can be studied alongside symptoms, cognitive function, imaging, and physiological biomarkers.

As these datasets become better connected, sport can move from reacting only after a visible problem towards understanding patterns earlier, managing exposure more intelligently and asking better questions about performance, recovery and long-term brain health.

The emerging evidence is serious, and it should not be diluted. Equally, responsible communication must avoid turning early findings into deterministic claims.

Fear can change behaviour, but trust is built through accuracy. The strongest case for objective brain-health monitoring is therefore neither alarmist nor complacent: repeated head impacts deserve attention, the science is advancing rapidly, and better measurement gives sport a practical way to respond.

The future of brain health will not rely on one number. It will be built by combining high-quality exposure data, biological science, and clinical expertise, then following athletes over time.